Tekla Capital Management LLC Revance Therapeutics, Inc. Transaction History

Tekla Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$24.03 - $29.97 $5.14 Million - $6.41 Million	-213,808 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$23.41 - $28.34 $3 Million - $3.63 Million	127,968 Added 149.08%	213,808 $6.06 Million
Q4 2019 Feb 13, 2020	BUY	$11.66 - $20.15 $1 Million - $1.73 Million	85,840 New	85,840 $1.39 Million
Q4 2018 Feb 13, 2019	SELL	$18.06 - $24.96 $1.41 Million - $1.94 Million	-77,919 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$27.45 - $33.35 $949,495 - $1.15 Million	34,590 Added 79.83%	77,919 $2.14 Million
Q1 2018 May 14, 2018	BUY	$29.15 - $37.4 $323,681 - $415,289	11,104 Added 34.46%	43,329 $1.34 Million
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $791,123 - $1.17 Million	32,225	32,225 $1.15 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.